Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 16, 2026Cancer Discovery

SEZ6-Targeted ADC Shows Preliminary Efficacy in Small Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Discussion

Loading...

Member takes

Overview

Phase I trial evaluates SEZ6-targeted ABBV-706 efficacy in relapsed/refractory SCLC, suggesting further research is needed.

Key Points

  • Determine the safety and efficacy of ABBV-706 in patients with relapsed/refractory small cell lung cancer.
  • Phase I clinical trial with 240 patients, including 124 with SCLC.
  • Monotherapy with ABBV-706 administered intravenously every three weeks.
  • Analysis of safety, tolerability, pharmacokinetics, immunogenicity, and efficacy.
  • Objective response rate of 52% in SCLC patients, with median overall survival of 11.3 months.
  • 93% of patients experienced treatment-related adverse events, primarily anemia and neutropenia.
  • Lower dose (1.8 mg/kg) associated with longer duration of response and fewer severe adverse events.

Cite This Study

A 2026 study studied this question.

synapsesocial.com/papers/6a5874c22b46c88ba9ad0bd8https://doi.org/10.1158/2159-8290.cd-rw2026-065
View Full Paper
Ask AI
Bookmark
Share